Natalie S. Callander, MD, on Multiple Myeloma: Cost Effectiveness of Drugs Used to Treat Relapsed/Refractory Disease

Posted: Wednesday, September 6, 2017

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses the cost effectiveness of carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma, an issue critically important to patients, providers, and NCCN panel members.